We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $1.94B
1-Year Est. Return 374.45%
This Fund
S&P 500
This Quarter Est. Return
+75.99%
1 Year Est. Return
+374.45%
3 Year Est. Return
+1,279.72%
5 Year Est. Return
+2,528.28%
10 Year Est. Return
–
AUM
$1.76B
AUM Growth
+$607M
Cap. Flow
+$235M
Cap. Flow %
13.41%
Top 10 Hldgs %
43.13%
Holding
124
New
28
Increased
25
Reduced
20
Closed
29

Top Buys

Rank Stock Value
1
PRAX icon
Praxis Precision Medicines
PRAX
+$34.5M
2
CYTK icon
Cytokinetics
CYTK
+$28M
3
VTYX
Ventyx Biosciences
VTYX
+$19.1M
4
ROIV icon
Roivant Sciences
ROIV
+$17.8M
5
FBRX icon
Forte Biosciences
FBRX
+$17.3M

Top Sells

Rank Stock Value
1
VRNA
Verona Pharma
VRNA
+$66.7M
2
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$56.3M
3
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$42.8M
4
MRUS
Merus
MRUS
+$26.9M
5
SLNO
Soleno Therapeutics
SLNO
+$13.5M

Sector Composition

Rank Sector Weight
1 Healthcare 76.68%
2 Financials 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RCUS icon
51
Arcus Biosciences
RCUS
$3.6B
$7.15M 0.41%
+300,000
New +$6.12M
SGMT icon
52
Sagimet Biosciences
SGMT
$455M
$6.8M 0.39%
1,148,245
+798,245
+228% +$5.74M
KPTI icon
53
Karyopharm Therapeutics
KPTI
$150M
$6.55M 0.37%
+889,575
New +$5.44M
ASND icon
54
Ascendis Pharma A/S
ASND
$16.6B
$6.4M 0.36%
+30,000
New +$6.2M
SMMT icon
55
PUT
Summit Therapeutics
SMMT
$10.7B
$6.12M 0.35%
350,000
– –
VRCA icon
56
Verrica Pharmaceuticals
VRCA
$100M
$5.88M 0.33%
+707,338
New +$3.92M
ENGN icon
57
enGene Therapeutics
ENGN
$125M
$5.81M 0.33%
643,370
+566,370
+736% +$4.54M
NAMSW icon
58
NewAmsterdam Pharma Warrant
NAMSW
$84.9M
$5.63M 0.32%
245,000
– –
RZLT icon
59
Rezolute
RZLT
$437M
$5.55M 0.32%
2,351,144
+251,144
+12% +$1.97M
AVDL
60
DELISTED
Avadel Pharmaceuticals
AVDL
$5.39M 0.31%
+250,000
New +$4.85M
CLYM
61
Climb Bio
CLYM
$729M
$5.2M 0.3%
1,300,000
– –
IMVT icon
62
Immunovant
IMVT
$8.23B
$5.08M 0.29%
200,000
-100,000
-33% -$2.23M
PRQR icon
63
ProQR Therapeutics
PRQR
$244M
$4.96M 0.28%
2,454,278
-1,145,722
-32% -$2.68M
DNTH icon
64
Dianthus Therapeutics
DNTH
$5.63B
$4.74M 0.27%
115,000
-147,100
-56% -$5.7M
ARWR icon
65
Arrowhead Research
ARWR
$10.1B
$4.65M 0.26%
+70,000
New +$3.43M
IBIO icon
66
iBio
IBIO
$68.6M
$3.97M 0.23%
+2,057,200
New +$2.81M
NXTC icon
67
NextCure
NXTC
$22.3M
$3.51M 0.2%
247,294
+55,412
+29% +$574K
CRNX icon
68
Crinetics Pharmaceuticals
CRNX
$8.88B
$3.49M 0.2%
75,000
– –
AMGN icon
69
Amgen
AMGN
$197B
$3.27M 0.19%
+10,000
New +$3.17M
BLTE
70
Belite Bio
BLTE
$6.22B
$3.2M 0.18%
+20,000
New +$2.37M
AVBP icon
71
ArriVent BioPharma
AVBP
$1.4B
$3.02M 0.17%
+150,000
New +$3.12M
MRSN
72
DELISTED
Mersana Therapeutics
MRSN
$2.89M 0.16%
+100,000
New +$1.9M
OACCU
73
Oaktree Acquisition Corp III Life Sciences Unit
OACCU
$2.65M 0.15%
250,000
– –
ABUS icon
74
CALL
Arbutus Biopharma
ABUS
$873M
$2.51M 0.14%
521,900
+310,400
+147% +$1.4M
AVR
75
Anteris Technologies
AVR
$812M
$2.43M 0.14%
486,684
+36,684
+8% +$168K
1 2
3
4 5

Similar funds

FM
Foster & Motley Cincinnati, Ohio $1.94B AUM 21.65% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $1.94B AUM 20.3% 1-Year Est. Return
HCL
Heard Capital LLC Chicago, Illinois $1.93B AUM 21.66% 1-Year Est. Return
OCM
Osterweis Capital Management San Francisco, California $1.94B AUM 20.77% 1-Year Est. Return
MWA
Midland Wealth Advisors Effingham, Illinois $1.94B AUM 14.31% 1-Year Est. Return
AF
Advisornet Financial Minnetonka, Minnesota $1.93B AUM 18.43% 1-Year Est. Return
NFG
Nations Financial Group Cedar Rapids, Iowa $1.94B AUM 25.76% 1-Year Est. Return
HC
Hamilton Capital Columbus, Ohio $1.93B AUM

Affinity Asset Advisors's Q4 2025 Portfolio in Review

As of Q4 2025, Affinity Asset Advisors held 124 positions worth $1.76B, up 53% from $1.15B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Affinity Asset Advisors deployed $235M of net new capital in Q4 2025, opening 28 new positions and adding to 25 existing holdings. Its largest new stake was Praxis Precision Medicines: 185,000 shares worth $54.5M.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, down from 85% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Madrigal Pharmaceuticals, an estimated $42.8M trimmed.

  • Affinity Asset Advisors's largest Q4 2025 buy was Praxis Precision Medicines: 185,000 shares worth $54.5M.
  • Affinity Asset Advisors added most to Cytokinetics in Q4 2025, an estimated $28M increase.
  • Affinity Asset Advisors's biggest Q4 2025 reduction was Madrigal Pharmaceuticals, cutting an estimated $42.8M.
  • Affinity Asset Advisors fully exited Verona Pharma in Q4 2025, selling an estimated $66.7M.
  • Affinity Asset Advisors's ten largest holdings make up 43% of its $1.76B portfolio in Q4 2025.
  • Affinity Asset Advisors opened 28 new positions and closed 29 in Q4 2025.
  • Affinity Asset Advisors's portfolio value rose 53% quarter-over-quarter to $1.76B.

Based on Affinity Asset Advisors's 13F filing for Q4 2025, filed 13 Feb 2026.